The US FDA has officially announced that the shortage of popular weight-loss drugs Ozempic and Wegovy, manufactured by Novo Nordisk, is over. This resolution ends a years-long deficit, which has caused substantial disruption in the market, particularly affecting companies like Hims & Hers. Following the announcement, shares of Hims & Hers tumbled as much as 26%, highlighting investor concerns over increased competition and challenges from the restored supply of semaglutide. The end of the shortage also poses significant threats to off-brand versions of the drugs, heralding a shift in the landscape of GLP-1 pharmaceuticals. Novo Nordisk shares increased in value, while analysts speculate about a potential reset for Hims & Hers as they navigate the new market conditions.